Table 11.
Pathogen, Antimicrobial | Hospital Wardsc | Hospital ICUs | Hospital Oncology Units | LTACHs | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
No. Reported |
% Tested |
% NSb |
No. Reported |
% Tested |
% NSb |
No. Reported |
% Tested |
% NSb |
No. Reported |
% Tested |
% NSb |
|
Staphylococcus aureus | 5,386 | 2,497 | 1,163 | 1,217 | ||||||||
OX/CEFOX/METH (MRSA) | 91.0 | 53.8 | 90.7 | 50.0* | 91.2 | 45.8* | 96.5 | 77.6* | ||||
Enterococcus faecium | 1,673 | 1,981 | 1,670 | 691 | ||||||||
Vancomycin (VRE) | 94.9 | 78.3 | 94.5 | 84.5* | 94.5 | 81.6* | 98.3 | 84.4* | ||||
Enterococcus faecalis | 2,636 | 2,117 | 664 | 1,314 | ||||||||
Vancomycin (VRE) | 93.6 | 10.7 | 93.0 | 8.5* | 89.9 | 7.4* | 95.4 | 18.0* | ||||
Selected Klebsiella spp | 3,344 | 1,708 | 1,441 | 1,158 | ||||||||
ESCs | 81.9 | 25.2 | 83.0 | 29.6* | 85.5 | 19.7* | 92.3 | 49.6* | ||||
Carbapenems (CRE) | 74.9 | 8.4 | 76.9 | 11.0* | 73.6 | 4.9* | 88.3 | 24.7* | ||||
MDR | 90.9 | 15.7 | 90.5 | 20.2* | 91.8 | 12.5* | 97.8 | 40.0* | ||||
Escherichia coli | 2,279 | 1,129 | 2,667 | 394 | ||||||||
ESCs | 81.7 | 27.4 | 82.2 | 29.8 | 84.7 | 28.3 | 89.3 | 40.3* | ||||
Carbapenems (CRE) | 74.6 | 1.2 | 73.9 | 2.4* | 76.6 | 1.4 | 87.6 | 2.3 | ||||
FQs | 91.8 | 47.1 | 90.4 | 43.2* | 90.3 | 65.3* | 96.2 | 60.2* | ||||
MDR | 91.0 | 14.1 | 88.8 | 14.4 | 90.1 | 17.6* | 94.7 | 26.3* | ||||
Enterobacter spp | 1,453 | 1,078 | 532 | 383 | ||||||||
Cefepime | 74.2 | 10.5 | 74.5 | 12.2 | 77.6 | 10.9 | 77.0 | 17.3* | ||||
Carbapenems (CRE) | 80.2 | 4.7 | 76.2 | 7.2* | 78.0 | 7.2 | 86.2 | 9.4* | ||||
MDR-2 | 91.5 | 6.2 | 89.6 | 7.7 | 90.0 | 7.1 | 95.6 | 13.7* | ||||
Pseudomonas aeruginosa | 1,407 | 1,061 | 701 | 495 | ||||||||
AMINOs | 93.3 | 12.8 | 90.9 | 14.9 | 92.6 | 8.9* | 96.2 | 23.5* | ||||
ESCs-2 | 92.0 | 21.9 | 90.2 | 26.5* | 91.2 | 15.2* | 94.9 | 37.7* | ||||
FQs-2 | 92.0 | 23.5 | 89.8 | 27.1 | 91.9 | 22.5 | 96.4 | 41.9* | ||||
Carbapenems-2 | 80.0 | 19.8 | 77.5 | 26.3* | 81.9 | 19.2 | 88.7 | 37.4* | ||||
PIP/PIPTAZ | 86.9 | 15.5 | 85.6 | 20.2* | 88.2 | 12.5 | 87.7 | 29.3* | ||||
MDR-3 | 93.2 | 13.6 | 91.2 | 18.6* | 92.4 | 11.6 | 97.2 | 29.9* | ||||
Acinetobacter spp | 660 | 392 | 66 | 245 | ||||||||
Carbapenems-2 | 78.8 | 33.1 | 80.6 | 47.2* | 75.8 | 12.0* | 86.1 | 75.4* | ||||
MDR-4 | 94.1 | 34.6 | 92.6 | 46.6* | 93.9 | 12.9* | 99.6 | 76.6* |
Note. ICUs, intensive care units; LTACHs, long-term acute-care hospitals; Selected Klebsiella spp, K. oxytoca and K. pneumoniae; OX/CEFOX/METH, oxacillin, cefoxitin, or methicillin; MRSA, methicillin-resistant Staphylococcus aureus; VRE, vancomycin-resistant Enterococcus; ESCs, extended-spectrum cephalosporins (cefepime, cefotaxime, ceftazidime, or ceftriaxone); CRE, carbapenem-resistant Enterobacteriaceae (imipenem, meropenem, doripenem, or ertapenem); MDR, multidrug-resistant (NS to 1 drug in at least 3 of the following classes: ESCs, FQs, AMINOs, carbapenems (R only), PIPTAZ); MDR-2, multidrug-resistant (NS to 1 drug in at least 3 of the following classes: cefepime, FQs, AMINOs, carbapenems (R only), PIPTAZ); FQs: fluoroquinolones (ciprofloxacin, levofloxacin, or moxifloxacin); AMINOs, aminoglycosides (amikacin, gentamicin, or tobramycin); ESCs-2, extended-spectrum cephalosporins (cefepime or ceftazidime); FQs-2, fluoroquinolones (ciprofloxacin or levofloxacin); PIP, piperacillin; PIPTAZ, piperacillin/tazobactam; Carbapenems-2, imipenem, meropenem, or doripenem; MDR-3, multidrug-resistant (NS to 1 drug in at least 3 of the following classes: ESCs-2, FQs-2, AMINOs, carbapenems-2, PIP/PIPTAZ); MDR-4, multidrug-resistant (NS to 1 drug in at least 3 of the following classes: ESCs-2, FQs-2, AMINOs, carbapenems-2, PIP/PIPTAZ, ampicillin/sulbactam).
Statistically significantly different than %NS in hospital wards; P < .05.
Supplemental tables are available in the 2015–2017 Adult Antimicrobial Resistance Report Online Supplement that show the %NS separately for mucosal barrier injury laboratory-confirmed bloodstream infection (MBI-LCBI) and non–MBI-LCBIs within hospital oncology locations (https://www.cdc.gov/nhsn/datastat/index.html).
MRSA, VRE, and CRE data are presented as %R (ie, includes only those pathogens that tested resistant). All other phenotypes are shown as %NS (ie, includes pathogens that tested intermediate or resistant).
Location types are mutually exclusive. “Hospital wards” includes step-down units, mixed acuity units, and specialty care areas.